Literature DB >> 25555152

Engineering and exploitation of a fluorescent HIV-1 gp120 for live cell CD4 binding assays.

Lindsey M Costantini1, Susan C Irvin2, Steven C Kennedy3, Feng Guo1, Harris Goldstein2, Betsy C Herold2, Erik L Snapp4.   

Abstract

The HIV-1 envelope glycoprotein, gp120, binds the host cell receptor, CD4, in the initial step of HIV viral entry and infection. This process is an appealing target for the development of inhibitory drugs and neutralizing antibodies. To study gp120 binding and intracellular trafficking, we engineered a fluorescent fusion of the humanized gp120 JRFL HIV-1 variant and GFP. Gp120-sfGFP is glycosylated with human sugars, robustly expressed, and secreted from cultured human cells. Protein dynamics, quality control, and trafficking can be visualized in live cells. The fusion protein can be readily modified with different gp120 variants or fluorescent proteins. Finally, secreted gp120-sfGFP enables a sensitive and easy binding assay that can quantitatively screen potential inhibitors of gp120-CD4 binding on live cells via fluorescence imaging or laser scanning cytometry. This adaptable research tool should aid in studies of gp120 cell biology and the development of novel anti-HIV drugs.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CD4; Diffusion; Envelope; FRAP; Fluorescent protein; HIV-1; Inhibitory antibody; Laser scanning cytometry; Neutralizing antibody; Superfolder GFP; gp120

Mesh:

Substances:

Year:  2014        PMID: 25555152      PMCID: PMC4323844          DOI: 10.1016/j.virol.2014.12.019

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  45 in total

1.  Monitoring chaperone engagement of substrates in the endoplasmic reticulum of live cells.

Authors:  Erik L Snapp; Ajay Sharma; Jennifer Lippincott-Schwartz; Ramanujan S Hegde
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-14       Impact factor: 11.205

2.  Broad HIV-1 neutralization mediated by CD4-binding site antibodies.

Authors:  Yuxing Li; Stephen A Migueles; Brent Welcher; Krisha Svehla; Adhuna Phogat; Mark K Louder; Xueling Wu; George M Shaw; Mark Connors; Richard T Wyatt; John R Mascola
Journal:  Nat Med       Date:  2007-08-26       Impact factor: 53.440

3.  Only five of 10 strictly conserved disulfide bonds are essential for folding and eight for function of the HIV-1 envelope glycoprotein.

Authors:  Eelco van Anken; Rogier W Sanders; I Marije Liscaljet; Aafke Land; Ilja Bontjer; Sonja Tillemans; Alexey A Nabatov; William A Paxton; Ben Berkhout; Ineke Braakman
Journal:  Mol Biol Cell       Date:  2008-07-23       Impact factor: 4.138

4.  Antigen selection from an HIV-1 immune antibody library displayed on yeast yields many novel antibodies compared to selection from the same library displayed on phage.

Authors:  D R Bowley; A F Labrijn; M B Zwick; D R Burton
Journal:  Protein Eng Des Sel       Date:  2007-01-22       Impact factor: 1.650

5.  Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.

Authors:  Xueling Wu; Zhi-Yong Yang; Yuxing Li; Carl-Magnus Hogerkorp; William R Schief; Michael S Seaman; Tongqing Zhou; Stephen D Schmidt; Lan Wu; Ling Xu; Nancy S Longo; Krisha McKee; Sijy O'Dell; Mark K Louder; Diane L Wycuff; Yu Feng; Martha Nason; Nicole Doria-Rose; Mark Connors; Peter D Kwong; Mario Roederer; Richard T Wyatt; Gary J Nabel; John R Mascola
Journal:  Science       Date:  2010-07-08       Impact factor: 47.728

6.  Kinetic mechanism for HIV-1 neutralization by antibody 2G12 entails reversible glycan binding that slows cell entry.

Authors:  Emily J Platt; Michelle M Gomes; David Kabat
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-30       Impact factor: 11.205

7.  Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins.

Authors:  Zhihai Si; Navid Madani; Jason M Cox; Jason J Chruma; Jeffrey C Klein; Arne Schön; Ngoc Phan; Liping Wang; Alyssa C Biorn; Simon Cocklin; Irwin Chaiken; Ernesto Freire; Amos B Smith; Joseph G Sodroski
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-29       Impact factor: 11.205

8.  The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

Authors:  Christopher N Scanlan; Ralph Pantophlet; Mark R Wormald; Erica Ollmann Saphire; Robyn Stanfield; Ian A Wilson; Hermann Katinger; Raymond A Dwek; Pauline M Rudd; Dennis R Burton
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

9.  Rab7 associates with early endosomes to mediate sorting and transport of Semliki forest virus to late endosomes.

Authors:  Andreas Vonderheit; Ari Helenius
Journal:  PLoS Biol       Date:  2005-06-21       Impact factor: 8.029

10.  A bright monomeric green fluorescent protein derived from Branchiostoma lanceolatum.

Authors:  Nathan C Shaner; Gerard G Lambert; Andrew Chammas; Yuhui Ni; Paula J Cranfill; Michelle A Baird; Brittney R Sell; John R Allen; Richard N Day; Maria Israelsson; Michael W Davidson; Jiwu Wang
Journal:  Nat Methods       Date:  2013-03-24       Impact factor: 28.547

View more
  3 in total

1.  Engineering and Characterization of a Fluorescent Native-Like HIV-1 Envelope Glycoprotein Trimer.

Authors:  Kwinten Sliepen; Thijs van Montfort; Gabriel Ozorowski; Laura K Pritchard; Max Crispin; Andrew B Ward; Rogier W Sanders
Journal:  Biomolecules       Date:  2015-10-23

2.  Structure and topology around the cleavage site regulate post-translational cleavage of the HIV-1 gp160 signal peptide.

Authors:  Erik Lee Snapp; Nicholas McCaul; Matthias Quandte; Zuzana Cabartova; Ilja Bontjer; Carolina Källgren; IngMarie Nilsson; Aafke Land; Gunnar von Heijne; Rogier W Sanders; Ineke Braakman
Journal:  Elife       Date:  2017-07-28       Impact factor: 8.140

3.  HIV-1 gp120 Promotes Lysosomal Exocytosis in Human Schwann Cells.

Authors:  Gaurav Datta; Nicole M Miller; Zahra Afghah; Jonathan D Geiger; Xuesong Chen
Journal:  Front Cell Neurosci       Date:  2019-07-17       Impact factor: 5.505

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.